Akero Therapeutics ($AKRO) announced significant histological improvements in patients with MASH (Metabolic Associated Fatty Liver Disease) after 96 weeks in its Phase 2b HARMONY study. The study's results, which focused on the company's lead experimental drug, efruxifermin (EFX), showed notable improvements in liver scarring. This comes at a time when no drugs are currently approved to treat MASH, highlighting the potential impact of Akero's research. The study also indicated that longer treatment durations could lead to better liver outcomes for MASH patients. Despite concerns about bone mineral density loss in some patients, experts believe this is manageable and does not overshadow the drug's benefits in reversing liver fibrosis. Akero's stock saw a 27.7% increase in pre-market trading following the announcement.
The liver disease MASH has become the new target for obesity drugs in development. Akero Therapeutics reports that extending treatment with its experimental drug from six months to two years resulted in better outcomes for patients. https://t.co/CFdxu1LP7D
$AKRO $MDGL if you liked resmetirom, you'll love efruxifermin. 2 trailblazers in MASH-fibrosis. And with larger p3 population+ longer duration, EFX will most likely also hit stat sig in cirrhosis. https://t.co/TSsksbYBn9
Akero strengthens MASH drug’s case with new study data https://t.co/moz4Cnb0NP $AKRO by @BentheFidler
After a whiplash rise and fall, Akero has bounced back with 96-week data linking efruxifermin to significant improvements in liver scarring in MASH. $AKRO https://t.co/YzLHZc4nOt
Akero strengthens MASH drug’s case with new study data https://t.co/O9YlOY0uK7 $AKRO + 27% $MDGL $VKTX $ETNB + 26%
$AKRO (+27.7% pre) Akero Therapeutics (AKRO) Posts Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study - SI https://t.co/CfUdvAOQZ5
Seeing skepticism on Biotwitter on the $AKRO data. But I doubt any hepatologist would react the same. 3-4% BMD loss likely reversible with 1-2 injections of Denosumab. Reversing fibrosis is way way harder. https://t.co/jmDG08siob
$AKRO on bone mineral density issue: 1) many post-menopausal women in study, expected to lose ~1% BMD per year 2) apparent stat sig bone loss driven by surprising INCREASE in BMD in pbo group
'pts come in w/ relatively poor bone health .. pt pop in gen'l .. lots of women in the post-menopausal age group .. expected over time ... 1-1.5%/yr expected .. ranges aren't that surprising .. one aspect surprising .. lumbar spine region - placebo actually increased.." $akro
$AKRO will bone mineral density issue weigh heavily on stock today?
$AKRO sees big further improvements in liver fibrosis going from 24 to 96 weeks. It now clearly looks stronger than $MDGL's (still up pre-market w/ PDUFA next week) for which we have 52 week data. https://t.co/JLtD83R71E
No drugs are currently approved to treat MASH, an increasingly common liver disease, but Akero and Madrigal appear to be getting closer. https://t.co/pFm9edNyB5
⚠️ AKERO'S LEAD DRUG HELPS IMPROVE SCARRING IN FATTY LIVER DISEASE PATIENTS (Reuters) Akero Therapeutics said on Monday its lead experimental drug to treat a type of fatty liver disease helped improve scarring in patients' organ after 96 weeks, meeting the main goal of a…
$AKRO 🇺🇸 Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study https://t.co/DhZGFsEJe5 https://t.co/6TwtOmndGU
$AKRO --> Longer treatment gave better liver outcomes for MASH patients, Akero drug study shows https://t.co/MbmzIVVl3H 96-week results from EFX HARMONY study
$AKRO Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study. https://t.co/g3zbY5tyQz